Adult Subjects With Uncontrolled Type 2 Diabetes

Objectives

1. To assess the safety, tolerability and initial anti-diabetic activity of MLR-1023 in
subjects with uncontrolled mild to moderate type 2 diabetes mellitus

2. To evaluate the pharmacokinetics of MLR-1023 and the major metabolite, MLR-1023-M1
following 28 days of repeat dosing

Design and Outcomes

The study is a randomized, double blind, placebo-controlled, parallel group study of
MLR-1023 in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and
exercise therapy.

A subset of subjects per dose group will have additional samples analyzed to measure signs
of MLR-1023.

Inclusion Criteria:

1. Diagnosed with uncontrolled T2DM who have received diet and exercise therapy for at
least 3 months prior to screening, aged ≥ 18 - ≤ 75 years

2. Females must be post-menopausal, unable to conceive, or test negative for pregnancy
via blood test and use barrier contraception

3. BMI ranging from ≥ 20 to ≤ 40 kg/m2

4. Fasting plasma glucose values of up to 240 mg/dL at screening, after wash-out (visit
2) and after placebo run-in (visit 3)

5. (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior
exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening

Exclusion Criteria:

1. History of Type 1 diabetes

2. History of more than 1 episode of severe hypoglycemia within 6 months prior to
screening, or a current diagnosis of hypoglycemia unawareness.

3. Hospitalizations or Emergency room visits that would impact patient safety or data
interpretation:

1. Due to poor glucose control in the 6 months prior to screening or

2. Any bariatric surgical procedures for weight loss.

4. Significant change of body weight (>10%) in the 3 months before screening

5. Proliferative retinopathy or maculopathy within the 6 months before screening or
requiring acute treatment, or severe neuropathy